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Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CaliforniaBACKGROUND & AIMS: Anti–tumor necrosis factor (anti-TNF)
therapies are the most widely used biologic drugs for treating
immune-mediated diseases, but repeated administration can
induce the formation of anti-drug antibodies. The ability to
identify patients at increased risk for development of anti-drug
antibodies would facilitate selection of therapy and use of
preventative strategies. METHODS: We performed a genome-
wide association study to identify variants associated with
time to development of anti-drug antibodies in a discovery
cohort of 1240 biologic-naïve patients with Crohn’s disease
starting infliximab or adalimumab therapy. Immunogenicity
was defined as an anti-drug antibody titer 10 AU/mL using a
drug-tolerant enzyme-linked immunosorbent assay. Significant
association signals were confirmed in a replication cohort of178 patients with inflammatory bowel disease. RESULTS: The
HLA-DQA1*05 allele, carried by approximately 40% of Euro-
peans, significantly increased the rate of immunogenicity (haz-
ard ratio [HR], 1.90; 95% confidence interval [CI], 1.60–2.25; P¼
5.88  10–13). The highest rates of immunogenicity, 92% at 1
year, were observed in patients treated with infliximab mono-
therapy who carried HLA-DQA1*05; conversely the lowest rates
of immunogenicity, 10% at 1 year, were observed in patients
treated with adalimumab combination therapy who did not
carry HLA-DQA1*05. We confirmed this finding in the replication
cohort (HR, 2.00; 95% CI, 1.35–2.98; P ¼ 6.60  10–4). This
association was consistent for patients treated with adalimumab
(HR, 1.89; 95% CI, 1.32–2.70) or infliximab (HR, 1.92; 95% CI,
1.57–2.33), and for patients treated with anti-TNF therapy alone
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Anti-tumor necrosis factor (anti-TNF) therapies are the
most widely used biologic drugs for treating immune-
mediated diseases, but repeated administration can
induce the formation of anti-drug antibodies, increasing
the risk of treatment failure.
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AT(HR, 1.75; 95% CI, 1.37–2.22) or in combination with
an immunomodulator (HR, 2.01; 95% CI, 1.57–2.58).
CONCLUSIONS: In an observational study, we found a genome-
wide significant association between HLA-DQA1*05 and the
development of antibodies against anti-TNF agents. A random-
ized controlled biomarker trial is required to determine
whether pretreatment testing for HLA-DQA1*05 improves pa-
tient outcomes by helping physicians select anti-TNF and com-
bination therapies. ClinicalTrials.gov ID: NCT03088449.NEW FINDINGS
In a genome-wide association study, we identified a
variant (HLA-DQA1*05) that increases risk of
development of antibodies against infliximab and
adalimumab 2-fold in patients with Crohn’s disease,
regardless of concomitant immunomodulator use.Keywords: PANTS; GWAS; Loss Of Response; Drug Persistence.
nti–tumor necrosis factor (anti-TNF) therapies are
LIMITATIONS
The study was limited to patients of European descent,
40% of whom carry the risk allele.
IMPACT
Testing patients for HLA-DQA1*05 might help physicians
decide whether they should receive anti-TNF and
combination immunomodulator therapy.Athe most widely used biologics for treating immune-
mediated diseases and in 2018 accounted for a global
expenditure in excess of $23.5 billion.1 Repeated adminis-
tration often induces the formation of anti-drug antibodies
(immunogenicity), leading to treatment failure.2
Immunogenicity is more common in patients treated
with infliximab (a murine-human chimeric monoclonal
antibody) than adalimumab (a fully human monoclonal
antibody) and is a major cause of low anti-TNF drug level,
infusion reactions, and non-remission in patients with
Crohn’s disease.2,3 Combination immunomodulator therapy
reduces the risk of immunogenicity to both adalimumab and
infliximab, and for infliximab, improves treatment out-
comes.2,4–6 Despite these benefits, many patients are still
treated with anti-TNF monotherapy because of concerns
about the increased risk of adverse drug reactions, oppor-
tunistic infections, and malignancies associated with com-
bination therapy with immunomodulators.7–9
The ability to identify patients at increased risk of
immunogenicity may influence the choice of anti-TNF
treatment and the use of preventative strategies, including
combination therapy with immunomodulators. However,
our understanding of the cellular and molecular mecha-
nisms underpinning immunogenicity to biologics is limited.
Retrospective candidate gene studies have suggested vari-
ants in FCGR3A10 and HLA-DRB111,12 increase susceptibility
to immunogenicity to anti-TNF therapy. These associations
did not achieve genome-wide significance and are yet to be
independently replicated. Here, we report the first genetic
locus robustly associated with immunogenicity to anti-TNF
therapies.Abbreviations used in this paper: AIC, Akaike information criterion; CI,
confidence interval; HR, hazard ratio; IBD, inflammatory bowel disease;
TNF, tumor necrosis factor; UC, ulcerative colitis.
Most current article
© 2020 by the AGA Institute. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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The PANTS (Personalising Anti-TNF Therapy in Crohn’s
Disease) study is a United Kingdom–wide, multicenter, pro-
spective observational cohort reporting the treatment failure
rates of the anti-TNF drugs infliximab (originator, Remicade
[Merck Sharp & Dohme, Hertfordshire, UK] and biosimilar, CT-
P13 [Celltrion, Incheon, South Korea]), and adalimumab
(Humira [AbbVie, Cambridge, MA]) in 1610 anti–TNF-naïve
patients with Crohn’s disease.2
At inclusion, subjects were aged 6 years or older and had
active luminal Crohn’s disease involving the colon and/or small
intestine. Choice of anti-TNF drug and use of concomitantimmunomodulator therapy was at the discretion of the treating
physician as part of usual care. Patients were initially studied
for 12 months or until drug withdrawal. In the first year, study
visits were scheduled at first dose, post-induction (weeks 12–
14), weeks 30 and 54, and at treatment failure. For infliximab-
treated patients, additional visits occurred at each infusion.
After 12 months, patients were invited to continue follow-up
for an additional 2 years. Drug persistence was defined as the
duration of time from initiation of anti-TNF therapy to exit from
the study due to treatment failure. Patients who exited the
study for other reasons, declined to participate in the 2-year
extension, or were lost to follow-up were censored at the
time of last drug dose or study visit.
At each visit, serum infliximab or adalimumab drug and
anti-drug antibody levels were analyzed using total antibody
enzyme linked immunosorbent assays.13 See the
Supplementary Material for a detailed description of drug and
anti-drug antibody testing. The total antibody, unlike the more
commonly reported free antibody assay, includes a drug–
antibody disassociation step that allows the assessment of
anti-drug antibodies in the presence of drug. We defined
immunogenicity as an anti-drug antibody concentration of 10
AU/mL, irrespective of drug level, at 1 or more time points.
DNA was extracted from pretreatment blood samples from
1524 individuals in the PANTS cohort and genotyping under-
taken using the Illumina CoreExome microarray (Illumina, San
Diego, CA). See the Supplementary Material for a detailed
description of the genetic analyses. We excluded individuals of
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see Supplementary Figure 1), 1 individual from each related
pair (defined as a pi-hat >.187), and those with an outlying
number of missing or heterozygous genotypes. After quality
control, 1323 individuals remained in the study, of which
1240 had drug and anti-drug antibody level data available
(Supplementary Figure 2). With its case–control design, our
study had >80% power to detect genome-wide significant
evidence of association (a ¼ 5  10–8) to variants with a
minor allele frequency >22% and a relative risk >1.4
(Supplementary Figure 3).14 Baseline demographics for these
patients are shown in Supplementary Table 1.
Variants with a genotype call rate of <95% or with signif-
icant evidence of deviation from Hardy-Weinberg equilibrium
(P < 1  10–10) were excluded. Single-nucleotide poly-
morphisms were imputed via the Sanger Imputation Service
using the Haplotype Reference Consortium panel, and
7,578,947 variants with an information content metric score
0.4 were subsequently taken forward for analysis.15 HLA
types were imputed at 2- and 4-digit resolution for the
following loci: HLA-A, HLA-C, HLA-B, HLA-DRB1, HLA-DQA1,
HLA-DQB1, and HLA-DPB1. Long-read sequencing of these HLA
alleles was undertaken to assess the accuracy of our
imputation.
We assembled an independent cohort to replicate signifi-
cant findings from the discovery cohort. This comprised 107
Crohn’s disease, 64 ulcerative colitis, and 7 inflammatory bowel
disease (IBD)–type unclassified patients with cross-sectional
drug and anti-drug antibody levels measured as part of
routine clinical practice. The samples were genotyped using
either the Illumina CoreExome array (n ¼ 164)16 or the Affy-
metrix 500k array (n ¼ 14; ThermoFisher Scientific, Waltham,
MA).17 Quality control and imputation methods were the same
as in the discovery cohort.
Statistical Analysis
Rates of immunogenicity were estimated using the Kaplan-
Meier method. Clinical outcomes and genetic association tests
with time to anti-drug antibody development were performed
using multivariable Cox proportional hazards regression: sex,
drug type (infliximab or adalimumab), immunomodulator use,
and the first within-sample principal component were
included as covariates (Supplementary Table 2). Patients who
did not develop immunogenicity during the study were
censored at the point of last observation. Post-hoc sensitivity
analyses were undertaken to test our genetic findings with
immunogenicity, firstly, at progressively higher antibody
thresholds; secondly, to simulate a free-antibody assay; and
thirdly, excluding patients with a single anti-drug antibody
level 10 AU/mL and subsequent negative anti-drug anti-
bodies <10 AU/mL.
The Akaike information criterion (AIC) was used to
compare non-nested models to assess if the mode of inheri-
tance was dominant or additive, and to determine whether
HLA allele group, specific HLA alleles, or amino-acid sequence
best explained the association. The fixed-effects Q statistic
was used to perform tests of heterogeneity of effect; this test
is an extension of Cochran’s Q-test and examines whether the
observed effect size variability is larger than expected by
chance. Interaction tests of the differential effects of drug
type (infliximab vs adalimumab and Remicade [JanssenBiotech, Inc, Horsham, PA] vs CT-P13) and combination
therapy (immunomodulator vs no immunomodulator) condi-
tional on the genotype were performed. Mann-Whitney U
tests were used to compare serum levels of anti-drug anti-
bodies at week 54 stratified by anti-TNF drug and immuno-
modulator use.
Ethics
The South West Research Ethics committee approved the
study (Research Ethics Committee reference: 12/SW/0323) in
January 2013. Patients were included after providing informed,
written consent. The protocol is available online (www.
ibdresearch.co.uk).
Results
Within the first 12 months, 44% of patients developed
anti-drug antibodies (95% confidence interval [CI], 0.41–
0.48), and 62% of patients did so within 36 months (95% CI,
0.57–0.67). After correcting for immunomodulator use, the
rate of immunogenicity was greater in patients treated with
infliximab (n ¼ 742) than adalimumab (n ¼ 498) (hazard
ratio [HR], 3.21; 95% CI, 2.61–3.95; P ¼ 1.18  10–28). In a
model including drug type as a covariate, rates of immuno-
genicity were greater in patients treated with anti-TNF
monotherapy (n ¼ 544) compared to combination therapy
with immunomodulators (n ¼ 696) (HR, 2.30; 95% CI, 1.94–
2.75; P < 6.10  10–21).
A Locus Within the HLA Region Is Associated
With Time to Immunogenicity
We identified a genome-wide significant association on
chromosome 6 with time to development of immunoge-
nicity, with the most associated single-nucleotide poly-
morphism, rs2097432 (b38_pos: 6:32622994; HR, 1.70;
95% CI, 1.48–1.94; P ¼ 4.24  10–13), falling within the
major histocompatibility complex region (Figure 1 and
Supplementary Figures 4 and 5). We replicated this asso-
ciation in our independent cohort of 178 patients with IBD
(HR, 1.69; 95% CI, 1.26–2.28; P ¼ 8.80  10–4). A variant on
chromosome 11, rs12721026 (b38_pos: 11:116835452; HR,
0.46; 95% CI, 0.33–0.63; P ¼ 4.76  10–8) also reached
genome-wide significance in our discovery analysis,
although the association was not replicated in our inde-
pendent cohort (HR, 0.85; 95% CI, 0.49–1.44; P ¼ .51).
Fine-Mapping of the Signal in the HLA Region
At the HLA allele group level (2-digit resolution), only
HLA-DQA1*05 achieved genome-wide significance (HR,
1.90; 95% CI, 1.60–2.25; P¼ 5.88  10–13) (Figure 2). At the
specific allele level (4-digit resolution), no single allele
reached genome-wide significance. The 2 most common
HLA-DQA1*05 subtype alleles, HLA-DQA1*05:01 (HR, 1.57;
95% CI, 1.33–1.85; P ¼ 4.24  10–7) and HLA-DQA1*05:05
(HR, 1.48; 95% CI, 1.24–1.78; P ¼ 5.54  10–5), had similar
effects on time to immunogenicity and a model containing
these two 4-digit alleles was virtually indistinguishable from
a model including HLA-DQA1*05 only (AIC05 ¼ 6659.07 vs
AIC05:01&05:05 ¼ 6659.50). We did not identify any amino
acids that better fit the data than HLA-DQA1*05. We
Figure 1. A regional plot of the association results with the major histocompatibility complex (MHC) region on chromosome 6.
Midpoint positions of the HLA genes across the MHC region are shown in red on the x-axis. Single-nucleotide polymorphisms
(SNPs) that passed the genome-wide significance threshold (P ¼ 5  10–8) are shown above the red horizontal dashed line with
the most significant SNP in red. SNPs correlated with the lead SNP (r2 > 0.05) are color-coded from purple to yellow. Pairwise
genotype correlation (r2) between SNPs was calculated using genotype data from the non-Finnish European population of the
1000 Genomes Project.
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sequenced HLA genotypes at HLA-DQA1 (Supplementary
Table 3).
To formally assess the inheritance pattern of HLA-
DQA1*05 mediated immunogenicity, we compared the fit
of additive and dominant models and found that the domi-
nant model gave a better fit (AICDOM ¼ 6652.12 vs AICADD ¼
6659.07), and stronger association signal for HLA-DQA1*05
(HR, 1.90; 95% CI, 1.60–2.25; P ¼ 5.88  10–13) (Figure 3Figure 2. Effect sizes of the most strongly associated single-nu
on time to immunogenicity. Blue lines represent 95% CIs. Assoand Supplementary Table 4). We also looked for nonaddi-
tive effects across all other HLA alleles, but the model
assuming a dominant effect for HLA-DQA1*05 remained the
best fit to the data. The HLA-DQA1*05 association was
confirmed in our replication cohort (entire cohort (HR, 2.00;
95% CI, 1.35–2.98; P ¼ 6.60  10–4), Crohn’s disease-only
subset (HR, 2.26; 95% CI, 1.33–3.84; P ¼ .003), and ulcer-
ative colitis–only subset of the replication cohort (HR, 2.02;
95% CI, 1.08–3.79; P ¼ .03), again with a better fit for thecleotide polymorphisms (SNPs), HLA alleles, and amino acids
ciation test P values are shown in parentheses.
Figure 3. Kaplan-Meier
estimator showing the rate
of anti-drug antibody
development, stratified by
the number of HLA-
DQA1*05 alleles carried.
Orange, blue, and red
indicate 0, 1, and 2 copies
of DQA1*05 allele,
respectively. Carriers of 1
or 2 copies of the allele
have a similar rate of
immunogenicity develop-
ment, and a dominant
model is a better fit for the
data than an additive
model (AICDOM ¼ 6652.12
vs AICADD ¼ 6659.07). X-
axis truncated at 700 days,
due to the low number of
observations for longer
time periods.
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After conditioning on HLA-DQA1*05, we did not identify any
secondary signals of association with time to immunoge-
nicity within the major histocompatibility complex region
(Supplementary Figure 6).
Sensitivity analyses showed that the effect size of HLA-
DQA1*05 carriage on immunogenicity was similar across
subgroups (Figure 4A, 4B): firstly when the threshold for
defining immunogenicity was increased from 10 AU/mL to
150 AU/mL. Secondly when we simulated a drug-sensitive
instead of a drug-tolerant assay, where immunogenicity was
defined as an anti-drug antibody titer 10 AU/mL without
detectable drug (HR, 1.57; 95% CI, 1.23-2.01; P ¼ 3.66 
10–4). Thirdly when we removed patients with a one-off
transient anti-drug antibody level 10 AU/mL (HR, 1.94;
95% CI, 1.62–2.32; P ¼ 8.46  10–13).
The Effect of HLA-DQA1*05 Across Drug and
Treatment Regimes
While immunogenicity rates were lower with
adalimumab-treated compared to infliximab-treated pa-
tients, we did not detect a significant difference in the
effect of HLA-DQA1*05 on the immunogenicity rate for
these 2 drugs (HR, 1.89; 95% CI, 1.32–2.70 in adalimu-
mab-, HR, 1.92; 95% CI, 1.57–2.33 in infliximab-treated
patients; Phet ¼ .91) (Figure 5). We also found no sig-
nificant evidence for heterogeneity of effect of HLA-
DQA1*05 on immunogenicity between patients treated
with the infliximab originator, Remicade, and its bio-
similar CT-P13 (Phet ¼ .23) (Supplementary Figure 7).
Likewise, we did not detect any significant heterogeneity
of effect of HLA-DQA1*05 carriage on immunogenicity
for individuals on monotherapy (HR, 1.75; 95% CI,1.37–2.22) vs combination therapy (HR, 2.01; 95% CI,
1.57–2.58) with immunomodulators (Phet ¼ .14). In
addition, we did not identify any significant interactions
between HLA-DQA1*05 and the clinical covariates (drug
type: P ¼ .83; mono- vs combination therapy: P ¼ .71;
Remicade vs CT-P13: P ¼ .59).
The highest rates of immunogenicity, 92% at 1 year,
were observed in patients treated with infliximab mono-
therapy who carried HLA-DQA1*05 (Figure 6A).
Conversely, the lowest rates of immunogenicity, 10% at 1
year, were observed in patients treated with adalimumab
combination therapy who did not carry HLA-DQA1*05
(Figure 6B). Our final model, which includes HLA-
DQA1*05 status, sex, drug, and immunomodulator usage,
explained 18% of the variance in immunogenicity to anti-
TNF in our cohort.
Having demonstrated that HLA-DQA1*05 was associated
with time to immunogenicity, we sought associations with
anti-drug antibody titers after 1 year of treatment and
subsequent non-persistence on drug. Carriage of HLA-
DQA1*05 was associated with higher maximal anti-drug
antibody titers (Pinfliximab ¼ 8  10–10; Padalimumab ¼ .002).
We observed lower drug persistence rates to year 3 in pa-
tients treated with an anti-TNF drug without an immuno-
modulator. HLA-DQA1*05 carriage was associated with
lower drug persistence only in patients treated with adali-
mumab without an immunomodulator (Figure 7A, 7B); the
optimal model here used the interaction between immu-
nomodulator use and HLA-DQA1*05 (DQA1*05: HR, 1.40;
95% CI, 1.08–1.80; P ¼ .011, immunomodulator use: HR,
0.74; 95% CI, 0.58–0.94; P ¼ .014, interaction between
DQA1*05 and immunomodulator use: HR, 0.65; 95% CI,
0.45–0.95; P ¼ .026).
Figure 4. (A) Sensitivity
analysis of the effect size
of DQA1*05 association
and time to immunoge-
nicity. (B) Sensitivity anal-
ysis of the significance of
DQA1*05 association and
time to immunogenicity. In
the primary analyses,
immunogenicity was
defined as an anti-drug
antibody concentration
10 AU/mL, irrespective
of drug concentration (red
dot). We repeated the time
to immunogenicity anal-
ysis varying this definition
from 5 to 200 AU/mL.
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Immunogenicity to biologic therapies is a major
concern for patients, regulatory authorities, and the
pharmaceutical industry. We report the first genome-
wide significant association with immunogenicity to
anti-TNF therapy using the largest prospective cohort
study of infliximab and adalimumab in Crohn’s disease.
We have demonstrated that carriage of 1 or more
HLA-DQA1*05 alleles confers an almost 2-fold risk of
immunogenicity to anti-TNF therapy, irrespective ofconcomitant immunomodulator use or drug type (inflix-
imab [Remicade or CT-P13] or adalimumab). Fine-
mapping and confirmatory sequencing of the HLA
identified that the specific alleles HLA-DQA1*05:01 and
HLA-DQA1*05:05 mediated most of this risk. Carriage of
HLA-DQA1*05 was associated with higher anti-drug
antibody levels and lower drug persistence rates,
although further studies are needed to more accurately
quantify the relationship between HLA-DQA1*05 and the
risk of anti-TNF treatment failure.
Figure 5. HLA-DQA1*05 has a consistent effect on immunogenicity in different patient subgroups. We repeated the propor-
tional hazard association analysis, separating the full cohort into subgroups by drug and therapy type. Estimated HRs and SEs
between the pairings were compared using a heterogeneity of effects test (P > .05), suggesting that the effect of DQA1*05 on
immunogenicity is not affected by these clinical covariates. Blue lines represent 95% CIs. Association test P values are shown
in parentheses.
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ease, all patients treated with an anti-TNF should be pre-
scribed an immunomodulator to lower the risk of
immunogenicity. We hypothesize that for patients who carry
HLA-DQA1*05 in whom immunomodulators are contra-
indicated or not tolerated, clinicians might advise against
the use of anti-TNF drugs, particularly infliximab. This is
because 90% of patients who carry HLA-DQA1*05 who are
treated with infliximab monotherapy have evidence of
immunogenicity by week 54. In contrast, patients who do
not carry HLA-DQA1*05 might be given the choice between
adalimumab or infliximab combination therapy. Patients
without the risk allele and a history of adverse drug re-
actions to thiopurines and/or methotrexate, or who are at
high risk of opportunistic infections, might be spared the
additional risks of combination therapy and treated with
adalimumab monotherapy. A randomized controlled
biomarker trial is required to explore these hypotheses and
confirm whether HLA-DQA1*05 testing may help direct
treatment choices in order to improve clinical outcomes.
The shared genetic association between HLA-DQA1*05
and immunogenicity to infliximab and adalimumab may
explain the widely reported diminishing returns of switch-
ing between anti-TNF therapies at the time of loss of
response.18,19 If the immunogenic effect of HLA-DQA1*05
extends to other therapeutic antibodies, then subjects who
carry the variant may be candidates for non-antibody mo-
dality therapies, such as small molecule drugs. Allelic vari-
ation in the HLA-DQA1 gene has been linked to aberrant
adaptive immune responses. The HLA class II gene
HLA-DQA1 is expressed by antigen presenting cells and
encodes the a-chain of the HLA-DQ heterodimer that forms
part of the antigen-binding site where epitopes are pre-
sented to T-helper cells. Relevant to immunogenicity, car-
riage of HLA-DQA1*05 has been associated with celiacdisease, type 1 diabetes, and protection against rheumatoid
arthritis and pulmonary tuberculosis.20–24 Several hypoth-
eses have been proposed, but exactly how specific HLA al-
leles contribute to disease pathogenesis or, in this case,
increased immunogenicity, remains unknown.
HLA-DQ1A*05 may serve as a useful biomarker of
immunogenicity risk and may impact how the next-
generation of anti-TNF drugs are designed to minimize
HLA-DQA1*05 mediated immunogenicity. Previous studies
have shown that it is possible to map and eliminate po-
tential immunogenic T-cell epitopes with the aim of pro-
ducing safer and more durable biologic drugs.25,26 However,
caution needs to be exercised to ensure protein sequence
modifications designed to reduce the risk of immunoge-
nicity to patients carrying HLA-DQA1*05 do not put a
different group of patients at risk.
Multiple assays are available to detect anti-drug anti-
bodies and there is no universally accepted, validated
threshold to diagnose immunogenicity. We deliberately
chose a total or drug-tolerant assay that permits the mea-
surement of anti-drug antibodies in the presence of drug in
order to minimize the number of false-negative patients
assigned to the control group. We then validated the man-
ufacturer’s positivity threshold in independent experiments
in 500 drug-naïve controls and confirmed that the recom-
mend cutoff of 10 AU/mL corresponds to the 99th centile of
the anti-drug antibody titer distribution. In support of this
threshold, we have recently demonstrated that even
modestly elevated anti-drug antibodies levels (10–30 AU/
mL) at weeks 14 and 54 of treatment are associated with
lower drug levels at these time points, and non-remission at
week 54.2 In addition, sensitivity analyses confirmed that
the association and effect size between HLA-DQA1*05 and
immunogenicity remained at progressively higher diag-
nostic thresholds for immunogenicity, when we simulated a
Figure 6. (A) Anti-drug
antibody development—
infliximab. (B) Anti-drug
antibody development—
adalimumab. Kaplan-
Meier estimator showing
the rate of anti-drug anti-
body development (A, B)
stratified by carriage of
HLA-DQA1*05 alleles and
treatment regime. Dotted
lines indicate patients un-
dergoing anti-TNF mono-
therapy; solid lines
indicate combination ther-
apy with immunomodula-
tors. Red indicates carriers
of the HLA-DQA1*05 allele
(1 or 2 copies); blue in-
dicates noncarriers. For
both drugs and treatment
regimes, immunogenicity
rates are higher for HLA-
DQA1*05 carriers. The x-
axis was truncated at 700
days due to the low num-
ber of observations.
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antibodies. Finally, HLA-DQA1*05 was associated with the
quantitative trait of maximal anti-drug antibody titer.
We acknowledge several important limitations of this
study. Firstly, we may have underestimated the contribution
of HLA-DQA1*05 to immunogenicity because of the short
duration of follow-up in patients who did not continue in
the study beyond the first year. Secondly, because we
designed a schedule of visits to minimize patients’ incon-
venience, there were fewer assessments for those treated
with adalimumab than infliximab. As a result, we might haveunderestimated rates of immunogenicity among
adalimumab-treated patients.
Our genome-wide association study was limited to pa-
tients with luminal Crohn’s disease of European descent.
Given that HLA-DQA1*05 is not associated with Crohn’s
disease risk,27 the percentage of carriers among our patients
(39%) was similar to that reported in an independent
British population cohort (38%).28 As such, we hypothesize
that HLA-DQA1*05 will make a similar contribution to anti-
TNF immunogenicity in other patient populations where
the allele is not associated with disease susceptibility
Figure 7. (A) Drug persis-
tence—infliximab. (B) Drug
persistence—adalimumab.
Kaplan-Meier estimator
showing the rate of drug
persistence (A, B) stratified
by carriage of HLA-
DQA1*05 alleles and
treatment regime. Dotted
lines indicate patients un-
dergoing anti-TNF mono-
therapy; solid lines
indicate combination ther-
apy with immunomodula-
tors. Red indicates carriers
of the HLA-DQA1*05 allele
(1 or 2 copies); blue in-
dicates noncarriers. The x-
axis was truncated at 700
days due to the low num-
ber of observations.
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Due to the wide variation in the frequency of HLA-DQA1*05
across ethnic groups,28 further studies are required to
assess the contribution of HLA-DQA1*05 to immunogenicity
across populations. Whether HLA-DQA1*05 is also associ-
ated with immunogenicity to other biologic drugs also needs
to be determined.
We report the first genome-wide significant association
with immunogenicity to biologic drugs. Carriage of HLA-
DQA1*05 almost doubles the rate of anti-TNF anti-drug
antibody development, independent of immunomodulatoruse, for both infliximab and adalimumab. To minimize the
risk of immunogenicity, pretreatment genetic testing for
HLA-DQA1*05 may help personalize the choice of anti-TNF
and the need for combination therapy with an
immunomodulator.
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Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2019.09.041.
198 Sazonovs et al Gastroenterology Vol. 158, No. 1
CLINICAL
ATReferences
1. IQVIA Institute. The Global Use of Medicine in 2019
and Outlook to 2023. Available at: https://www.
iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-
use-of-medicine-in-2019-and-outlook-to-2023.pdf?_ ¼
1557505804444. Accessed July 1, 2019.
2. Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-
TNF treatment failure in anti-TNF-naive patients with active
luminal Crohn’s disease: a prospective, multicentre, cohort
study. Lancet Gastroenterol Hepatol 2019;1253:1–13.
3. Vermeire S, Gils A, Accossato P, et al. Immunogenicity of
biologics in inflammatory bowel disease. Therap Adv
Gastroenterol 2018;11:1756283X17750355.
4. Colombel JF, Sandborn WJ, Reinisch W, et al. Inflix-
imab, azathioprine, or combination therapy for Crohn’s
disease. N Engl J Med 2010;362:1383–1395.
5. Panaccione R, Ghosh S, Middleton S, et al. Combination
therapy with infliximab and azathioprine is superior to
monotherapy with either agent in ulcerative colitis.
Gastroenterology 2014;146:392–400.e3.
6. Matsumoto T, Motoya S, Watanabe K, et al.
Adalimumab monotherapy and a combination with
azathioprine for Crohn’s disease: a prospective, ran-
domized trial. J Crohns Colitis 2016;10:1259–1266.
7. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug
therapies and the risk of malignancy in Crohn’s disease:
results from the TREATTM Registry. Am J Gastroenterol
2014;109:212–223.
8. Osterman MT, Sandborn WJ, Colombel J-F, et al.
Increased risk of malignancy with adalimumab combi-
nation therapy, compared with monotherapy, for Crohn’s
disease. Gastroenterology 2014;146:941–949.
9. Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association
between use of thiopurines or tumor necrosis factor
antagonists alone or in combination and risk of lym-
phoma in patients with inflammatory bowel disease.
JAMA 2017;318:1679–1686.
10. Romero-Cara P, Torres-Moreno D, Pedregosa J, et al.
A FCGR3A polymorphism predicts anti-drug antibodies
in chronic inflammatory bowel disease patients treated
with anti-TNF. Int J Med Sci 2018;15:10–15.
11. Billiet T, Casteele N Vande, Stappen T Van, et al.
Immunogenicity to infliximab is associated with HLA-
DRB1. Gut 2015;64:1344–1345.
12. Liu M, Degner J, Davis JW, et al. Identification of HLA-
DRB1 association to adalimumab immunogenicity.
PLoS One 2018;13:e0195325.
13. Perry M, Bewshea C, Brown R, et al. Infliximab and
adalimumab are stable in whole blood clotted samples
for seven days at room temperature. Ann Clin Biochem
2015;52:672–674.
14. Johnson JL, Abecasis GR. GAS Power Calculator: web-
based power calculator for genetic association studies.
bioRxiv 2017:164343.
15. McCarthy S, Das S, Kretzschmar W, et al. A reference
panel of 64,976 haplotypes for genotype imputation. Nat
Genet 2016;48:1279–1283.
16. Lange KM de, Moutsianas L, Lee JC, et al. Genome-
wide association study implicates immune activation ofmultiple integrin genes in inflammatory bowel disease.
Nat Genet 2017;49:256–261.
17. Wellcome Trust Case Control Consortium. Genome-
wide association study of 14,000 cases of seven com-
mon diseases and 3,000 shared controls. Nature 2007;
447:661–678.
18. Panaccione R, Loftus EV, Binion D, et al. Efficacy and
safety of adalimumab in Canadian patients with moder-
ate to severe Crohn’s disease: results of the Adalimumab
in Canadian SubjeCts with ModErate to Severe Crohn’s
DiseaSe (ACCESS) trial. Can J Gastroenterol 2011;
25:419–425.
19. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab
induction therapy for Crohn disease previously treated
with infliximab. Ann Intern Med 2007;146:829.
20. Megiorni F, Pizzuti A. HLA-DQA1 and HLA-DQB1 in
Celiac disease predisposition: practical implications
of the HLA molecular typing. J Biomed Sci 2012;
19:88.
21. Oliveira-Cortez A, Melo AC, Chaves VE, et al. Do HLA
class II genes protect against pulmonary tuberculosis? A
systematic review and meta-analysis. Eur J Clin Micro-
biol Infect Dis 2016;35:1567–1580.
22. Reddy MPL, Wang H, Liu S, et al. Association between
type 1 diabetes and GWAS SNPs in the southeast US
Caucasian population. Genes Immun 2011;12:208–212.
23. Eleftherohorinou H, Hoggart CJ, Wright VJ, et al.
Pathway-driven gene stability selection of two rheuma-
toid arthritis GWAS identifies and validates new sus-
ceptibility genes in receptor mediated signalling
pathways. Hum Mol Genet 2011;20:3494–3506.
24. Ursum J, Weijden MAC van der, Schaardenburg D van,
et al. IL10 GGC haplotype is positively and HLA-
DQA1*05-DQB1*02 is negatively associated with radio-
graphic progression in undifferentiated arthritis.
J Rheumatol 2010;37:1431–1438.
25. De Groot AS, Knopp PM, Martin W. De-immunization of
therapeutic proteins by T-cell epitope modification. Dev
Biol (Basel) 2005;122:171–194.
26. Sathish JG, Sethu S, Bielsky M-C, et al. Challenges and
approaches for the development of safer immunomodu-
latory biologics. Nat Rev Drug Discov 2013;12:306–324.
27. Goyette P, Boucher G, Mallon D, et al. High-density
mapping of the MHC identifies a shared role for HLA-
DRB1*01:03 in inflammatory bowel diseases and het-
erozygous advantage in ulcerative colitis. Nat Genet
2015;47:172–179.
28. González-Galarza FF, Takeshita LYC, Santos EJM,
et al. Allele frequency net 2015 update: new features for
HLA epitopes, KIR and disease and HLA adverse drug
reaction associations. Nucleic Acids Res 2015;43:D784–
D788.
Author names in bold designate shared co-first authorship.
Received August 30, 2019. Accepted September 29, 2019.
Reprint requests
Address requests for reprints to: Carl A. Anderson, PhD, Genomics of
Inflammation and Immunity Research Group, Morgan Building, Wellcome
Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1SA, UK.
January 2020 HLA-DQA1*05 Carriage Associated With Immunogenicity to Infliximab and Adalimumab 199
CL
IN
IC
AL
ATe-mail: carl.anderson@sanger.ac.uk; or Tariq Ahmad, DPhil, Exeter IBD and
Pharmacogenetics Research Group, RILD Building, Barrack Road, Exeter
EX2 5DW, UK. e-mail: tariq.ahmad1@nhs.net.
Acknowledgments
The authors would like to acknowledge the study coordinators of the Exeter
IBD Research Group, United Kingdom, Marian Parkinson and Helen Gardner-
Thorpe, for their ongoing administrative support to the study. The authors
would also like to thank the National Institute for Health Research UK IBD
BioResourse for help establishing the replication cohort.
Transcript profiling: Summary statistics will be deposited on the NHGRI-EBI
GWAS Catalog upon publication. Genotype data that supports this study has
been deposited in the European Genome-phenome Archive under the
accession code EGAS00001000924.
Author contributions: T.A., C.A.A., J.C.B., G.A.H., C.M.B., T.J.M., M.H.P.,
P.M.I., and N.A.K. participated in the conception and design of the work:
C.M.B was the project manager and coordinated recruitment. A.S., L.M.,
D.L.R., J.C.B., C.A.A, M.R, G.J.W, and N.A.K. were involved in the
acquisition, analysis or interpretation of data. C.W.L., J.R.F.C., M.P., J.C.M.,
D.L.R., P.M.I., and N.A.K. were involved in the acquisition of the replication
cohort. The statistical analysis was performed by A.S., N.A.K., L.M., J.C.B.,
and C.A.A. Drafting of the manuscript was conducted by A.S., N.A.K., L.M.,
G.A.H., C.M.B., N.C., D.M., J.R.G., C.A.A, and T.A. All the authors
contributed to the critical review and final approval of the manuscript. T.A.
and C.A.A. obtained the funding for the study. All remaining authors
contributed by submitting a substantial number of samples in line with
International Committee of Medical Journal Editors criteria. Carl A. Anderson
and Tariq Ahmad contributed equally to this work.
Conflicts of interest
These authors disclose the following: Graham A. Heap reports non-financial
support from AbbVie, outside the submitted work; and he is now an
employee of AbbVie and owns stock in the company. Mark Reppell is an
employee of AbbVie and owns stock in the company. Gareth J. Walker has
received honoraria from AbbVie. Charlie W. Lees reports grants and personalfees from AbbVie, Amgen, Pfizer, and Samsung Bioepis. J.R. Fraser
Cummings reports personal fees from AbbVie, grants and personal fees from
Biogen, personal fees from MSD, Celltrion, NAPP, and Sandoz. Peter M.
Irving reports personal fees from AbbVie, Pfizer, Sandoz, Samsung and
Bioepis, grants from MSD; outside the submitted work. Dermot McGovern
reports grants and personal fees from Pfizer outside the submitted work.
James R. Goodhand received honoraria from AbbVie, for unrelated topics.
Tariq Ahmad has received unrestricted research grants, advisory board fees,
speaker honorariums, and support to attend international meetings from
AbbVie, Merck, Pfizer, NAPP, Celltrion, and Hospira. The remaining authors
disclose no conflicts.
Funding
PANTS is an investigator-led study funded by CORE (renamed Guts UK in
2018), the research charity of the British Society of Gastroenterology, and
by unrestricted educational grants from AbbVie Inc, USA, Merck Sharp &
Dohme Ltd, UK, NAPP Pharmaceuticals Ltd, UK, Pfizer Ltd, USA, Celltrion
Healthcare, South Korea, and Cure Crohn’s Colitis (Scottish IBD Charity).
HLA long-read sequencing was supported through a sponsored research
agreement with AbbVie Inc. The drug and anti-drug antibody assays were
provided at reduced cost by Immundiagnostik AG. Laboratory tests were
undertaken by the Exeter Blood Sciences Laboratory at the Royal Devon &
Exeter National Health Service Trust (https://www.exeterlaboratory.com).
The sponsor of the PANTS study is the Royal Devon and Exeter National
Health Service Foundation Trust. Aleksejs Sazonovs, Loukas Moutsianas,
Daniel L. Rice, Jeffrey C. Barrett, and Carl A. Anderson are funded by the
Wellcome Trust, who also funded the genotyping of all samples (206194).
Timothy J. McDonald is funded by a National Institute for Health Research
Health Education England Senior Lectureship. The views expressed in this
publication are those of the author(s) and not necessarily those of the
National Health Service, Health Education England, National Institute for
Health Research, or the Department of Health. None of the listed funders
had a role in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; preparation, review, and decision to
submit the manuscript for publication.
